News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AM-Pharma Holding BV Presents Positive Data From recAP Preclinical Study at American Society of Nephrology Meeting


11/8/2013 9:54:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BUNNIK, The Netherlands & ATLANTA--(BUSINESS WIRE)--AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today presents preclinical data on its drug candidate recAP in an Acute Kidney Injury (AKI) setting, at the American Society of Nephrology (ASN) meeting Kidney Week in Atlanta, GA, USA. The research was conducted by Prof. Dr. Can Ince and his team at the Department of Translational Physiology, Academic Medical Center, University of Amsterdam, the Netherlands.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES